Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva closes Cidra plant

Executive Summary

Teva announces Aug. 23 that it will cease production at its Cidra, Puerto Rico manufacturing facility in the fourth quarter as part of a "globalization rationalization strategy." During a recent earnings call, Teva said it wanted to "significantly reduce complexity" at the facility, which was inherited through its acquisition of Ivax, due to repeated problems (1"The Pink Sheet" Aug. 14, 2006, p. 7). The facility currently employs 550 personnel and originally manufactured 50 products, the majority of which Teva says have been transferred to other sites. The company anticipates the closure will result in approximately $45 mil. in cost savings in 2007...

You may also be interested in...

Teva’s Generic Zoloft Launch, And New Jerusalem Plant, Remain Idle

Teva's supply chain challenges appear to have caught up with the company in the form of further delays of its launch of Zoloft generics

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts